Download PDF
Arzneimittelforschung 2011; 61(2): 132-139
DOI: 10.1055/s-0031-1296179
Antibiotics · Antimycotics · Antiparasitics · Antiviral Drugs · Chemotherapeutics · Cytostatics
Editio Cantor Verlag Aulendorf (Germany)

Quantification of voriconazole in human plasma by high-performance liquid chromatography–electrospray ionization mass spectrometry: application to a bioequivalence study

Ying Cheng
1   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
2   Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, P. R. China
,
Zun-Jian Zhang
1   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
2   Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, P. R. China
,
Yuan Tian
1   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
2   Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, P. R. China
,
Wen-Jing Li
1   Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing, P. R. China
2   Center for Instrumental Analysis, China Pharmaceutical University, Nanjing, P. R. China
,
Wei Wei
3   Institute of Clinical Pharmacology, Anhui Medical University, Hefei, P. R. China
› Author Affiliations
Further Information

Publication History

Publication Date:
28 November 2011 (online)

    Permissions and Reprints

Abstract

A sensitive and specific liquid chromatography-electrospray ionization mass spectrometry (LC-ESI-MS) method was developed and validated for the identification and quantification of voriconazole (VRC, CAS 137234-62-9) in human plasma. Following liquid-liquid extraction, VRC and loratadine (internal standard, CAS 79794-75-5) were separated using a mobile phase comprised of methanol: water (0.1% formic acid) = 75:25 v/v on a Shimadzu Shim-pack VP-ODS C18 (150 × 2.0 mm ID, 5 μrn) column and analyzed by electrospray ionization mass spectrometry. The chromatographic separation was achieved in less than 6 min. The standard curves were linear (r = 0.9994) over the concentration range of 2-2000 ng/mL for VRC and had good accuracy and precision. Both intra- and inter-batch standard deviations were less than 15%. The method was successfully applied to study the comparative bioavailability of VRC tablets test vs. reference in healthy Chinese volunteers through the statistical comparison of pharmacokinetic parameters obtained with the two formulations.

Key words

Antifungal - Bioequivalence - CAS 137234-62-9 - HPLC-ESI-MS - Human plasma - Voriconazole
 

  • References

  • 1 Chandrasekar PH, Manavathu E.. Voriconazole: a second-generation triazole. Drugs Today. 2001; 37: 135-48
    PubMedGoogle Scholar
  • 2 Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht R, Thiel E et al Efficacy and safety of VRC in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002; 34: 563-71
    CrossrefPubMedGoogle Scholar
  • 3 Boyd AE, Modi S, Howard SI, Moore CB, Keevil BG, Denning DW. Adverse reactions to VRC. Clin Infect Dis. 2004; 39: 1241-4
    CrossrefPubMedGoogle Scholar
  • 4 Eiden C, Peyrière H, Cociglio M, Djezzar S, Hansel S, Blayac IP et al Network of the French Pharmacovigilance Centers. Adverse effects of voriconazole: analysis of the French Pharmacovigilance Database. Ann Pharmacother. 2007; 41: 755-63
    CrossrefPubMedGoogle Scholar
  • 5 Tan K, Brayshaw N, Tomaszewski K, Troke P, Wood N. Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities. J Clin Pharmacol. 2006; 46: 235-43
    CrossrefPubMedGoogle Scholar
  • 6 Imhof A, Schaer D, Schwaerz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly. 2006; 136: 739-42
    PubMedGoogle Scholar
  • 7 Eiden C, Peyrière H, Tichit R, Cociglio M, Amedro P, Blayac JP et al Inherited long QT syndrome revealed by antifungals drug-drug interaction. J Clin Pharm Ther. 2007; 32: 321-4
    CrossrefPubMedGoogle Scholar
  • 8 Perea S, Pennick GF, Modak A, Fothergill AW, Sutton DA, Sheehan DJ et al Comparison of high-performance liquid chromatographic and microbiological methods for determination of voriconazole levels in plasma. Antimicrob Agents Chemother. 2000; 44: 1209-13
    CrossrefPubMedGoogle Scholar
  • 9 Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V et al Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant. 2005; 35: 509-13
    CrossrefPubMedGoogle Scholar
  • 10 Smith J, Safdar N, Knasinski V, Simmons W, Bhavnani SM, Ambrose PG et al Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother. 2006; 50: 1570-2
    CrossrefPubMedGoogle Scholar
  • 11 Trifilio S, Pennick G, Pi J, Zook J, Golf M, Kaniecki K et al Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer. 2007; 109: 1532-5
    CrossrefPubMedGoogle Scholar
  • 12 Gage R, Stopher DA. A rapid HPLC assay for voriconazole in human plasma. J Pharm Biomed Anal. 1998; 17: 1449-53
    CrossrefPubMedGoogle Scholar
  • 13 Pennick GJ, Clark M, Sutton DA, Rinaldi MG. Development and validation of a high-performance liquid chromatography assay for voriconazole. Antimicrob Agents Chemother. 2003; 47: 2348-50
    CrossrefPubMedGoogle Scholar
  • 14 Simmel F, Soukup J, Zoerner A, Radke J, Kloft C. Development and validation of an efficient HPLC methodfor quantification of voriconazole in plasma and microdialysate reflecting an important target site. Anal Bioanal Chem. 2008; 392: 479-88
    CrossrefPubMedGoogle Scholar
  • 15 Wenk M, Drollb A, Rähenbühl S. Fast and reliable determination of the antifungal drug voriconazole in plasma using monolithic silica rod liquid chromatography. J Chromatogr B. 2006; 832: 313-6
    CrossrefPubMedGoogle Scholar
  • 16 Langman LJ, Boakye-Agyeman F. Measurement of voriconazole in serum and plasma. Clin Biochem. 2007; 40: 1378-85
    CrossrefPubMedGoogle Scholar
  • 17 Egle H, Trittler R, König A, Kmerer K. Fast, fully automated analysis of voriconazole from serum by LC-LC-ESI-MS-MS with parallel column-switching technique. J Chromatogr B. 2005; 814: 361-7
    CrossrefPubMedGoogle Scholar
  • 18 FDA: Guidance for Industry: Bioanalytical Method Validation. U.S. Department of Health and Human Services, Food and Drug Administration Center for Drug Evaluation and Research (CDER), and Center for Veterinary Medicine (CVM), 2001. http://www.fda.gov/cder/guidance/index.htm/
    PubMed